Citations

Showing 10 of 108162 citations.

A Simple and Quick Method for Loading Proteins in Extracellular Vesicles
Busatto, Sara , Iannotta, Dalila , Walker, Sierra A. , Marzio, Luisa Di , Wolfram, Joy , Di Marzio, Luisa , Wolfram, Joy

Mayo Clinic

Pharmaceuticals | April 13, 2021 | Volume: 14 | Issue: 4 | Pages: 356

10.3390/ph14040356 | PMID 33924377 Get It

Extracellular vesicles (EVs) mediate intercellular transport of biomolecular cargo in the body, making them promising delivery vehicles for bioactive compounds. Genetic engineering of producer cells has enabled encapsulation of therapeutic proteins in EVs. However, genetic engineering approaches can be expensive, time-consuming, and incompatible with certain EV sources, such as human plasma and bovine milk. The goal of this study was to develop a quick, versatile, and simple method for loading proteins in EVs post-isolation. Proteins, including CRISPR associated protein 9 (Cas9), were bound to cationic lipids that were further complexed with MDA-MB-231 cell-derived EVs through passive incubation. Size-exclusion chromatography was used to remove components that were not complexed with EVs. The ability of EVs to mediate intracellular delivery of proteins was compared to conventional methods, such as electroporation and commercial protein transfection reagents. The results indicate that EVs retain native features following protein-loading and obtain similar levels of intracellular protein delivery as conventional methods, but display less toxicity. This method opens up opportunities for rapid exploration of EVs for protein delivery.
Myelofibrosis: challenges for preclinical models and emerging therapeutic targets
Morsia, Erika , Gangat, Naseema

Mayo Clinic

Expert Opinion on Therapeutic Targets | April 12, 2021 | Volume: No volume available | Issue: No issue available | Pages: 1-12

10.1080/14728222.2021.1915992 | PMID 33844952 Get It

Differential mRNA Expression in Ileal Mucosal Biopsies of Patients With Diarrhea- or Constipation-Predominant Irritable Bowel Syndrome
Carlson, Paula, Chedid, Victor , Maselli, Daniel B. , Taylor, Ann, McKinzie, Sanna, Camilleri, Michael , Chedid, Victor G , Wang, Xiao‐Jing

Mayo Clinic

Clinical and Translational Gastroenterology | April 12, 2021 | Volume: 12 | Issue: 4 | Pages: e00329

10.14309/ctg.0000000000000329 | PMID 33843785 Get It

INTRODUCTION: Previous studies in patients with irritable bowel syndrome (IBS) showed immune activation, secretion, and barrier dysfunction in duodenal, jejunal, or colorectal mucosa. This study aimed to measure ileal mucosal expression of genes and proteins associated with mucosal functions. METHODS: We measured by reverse transcription polymerase chain reaction messenger RNA (mRNA) expression of 78 genes (reflecting tight junction proteins, chemokines, innate immunity, ion channels, and transmitters) and 5 proteins (barrier, bile acid receptor, and ion exchanger) in terminal ileal mucosa from 11 patients with IBS-diarrhea (IBS-D), 17 patients with IBS-constipation (IBS-C), and 14 healthy controls. Fold changes in mRNA were calculated using 2 (−Δ, ΔCT) formula. Group differences were measured using analysis of variance. Protein ratios relative to healthy controls were based on Western blot analysis. Nominal P values ( P < 0.05) are reported. RESULTS: In ileal mucosal biopsies, significant differences of mRNA expression in IBS-D relative to IBS-C were upregulation of barrier proteins (TJP1, FN1, CLDN1, and CLDN12), repair function (TFF1), and cellular functions. In ileal mucosal biopsies, mRNA expression in IBS-C relative to healthy controls was reduced GPBAR1 receptor, myosin light chain kinase (MYLK in barrier function), and innate immunity (TLR3), but increased mRNA expression of cadherin cell adhesion mechanisms (CTNNB1) and transport genes SLC9A1 (Na-H exchanger [NHE1]) and INADL (indirect effect on ion transport). DISCUSSION: These data support a role of ileal mucosal dysfunction in IBS, including barrier dysfunction in IBS-D and alterations in absorption/secretion mechanisms in IBS-C.
Gastrointestinal defect closure using a novel through-the-scope helix tack and suture device compared to endoscopic clips in a survival porcine model (with video)
Hernandez, Ariosto, Marya, Neil B. , Sawas, Tarek , Rajan, Elizabeth , Gades, Naomi M. , Song, Louis M. Wong Kee , Buttar, Navtej , Wong Kee Song, Louis M, Hernandez, Ariosto, Marya, Neil B. , Dayyeh, Barham K. Abu , Storm, Andrew C.

Mayo Clinic

Endoscopy International Open | April 12, 2021 | Volume: 09 | Issue: 04 | Pages: E572-E577

10.1055/a-1370-9256 | PMID 33860074 Get It

Abstract Background and aims Endoscopic resections are associated with bleeding and perforation and may be managed with through-the-scope (TTS) clips, over-the-scope clips and endoscopic suturing. The aim of this preclinical study was to compare technical success of closure using a novel TTS tissue helix tack and suture device (X-Tack) to TTS clips in a porcine model. Materials and methods Four subjects underwent 40 mucosal resections, diameter range 25–50 mm, in the stomach (n = 24) and colon (n = 16). Closures were randomized to X-Tack (n = 24) or clip (n = 16). Animals underwent weekly endoscopic follow-up for 4 weeks. Results Technical closure with X-Tack was successful in 24 of 24 (100 %) cases and with clips in 13 of 16 cases (81.3 %) (P = 0.0001). One colonic perforation occurred and was successfully managed using X-Tack. The rate of healing was not statistically different between the groups, and all sites healed at 4 weeks including the perforation and were confirmed by histology. Conclusions Compared to TTS clip, X-Tack is superior for effecting large mucosal defect closure, including durable sealing of full-thickness perforation. There was no difference in rate of healing between devices.
Analytical and Clinical Considerations in Implementing the Roche Elecsys Troponin T Gen 5 STAT Assay
Wockenfus, Amy M., Katzman, Brooke M. , Baumann, N, Jaffe, Allan S. , Karon, Brad S. , Donato, Leslie J. , Jaffe, Allan S.

Mayo Clinic

American Journal of Clinical Pathology | April 12, 2021 | Volume: 156 | Issue: 6 | Pages: 1121-1129

10.1093/ajcp/aqab082 | PMID 34223873 Get It

Abstract Objectives To evaluate the analytical and clinical performance characteristics of the fifth-generation troponin T reagent. Methods Troponin T was measured in 2,332 paired serum and plasma samples from emergency department and hospital patients using the fourth- and fifth-generation reagents. Testing was repeated after recentrifugation to determine the frequency of analytical outliers and percentage of patients with elevated values for each assay. We conducted separate experiments to determine the effects of biotin and hemolysis interference, as well as measure interinstrument variability, for fifth-generation troponin T. Results Analytic outliers occurred more frequently using the fifth-generation reagent (3.4%) compared with the fourth-generation reagent (1.0%). The frequency of elevated troponin T above the 99th percentile upper reference limit was 26% for the fourth-generation reagent and 52% for the fifth-generation reagent. Clinically significant assay interference by biotin was observed at 20 ng/mL, but hemolysis interference was not observed until an H index of 150. Instrument-to-instrument variability between e411 and e601/602 instrument platforms is predicted to confound clinical interpretation of troponin changes. Conclusions Analytical outliers and instrument-to-instrument variability are the two analytical variables most likely to confound interpretation of changes in fifth-generation troponin T results over time.
Real-Time Cardiac Magnetic Resonance Imaging
Borlaug, Barry A. , Nelson, Michael D. , Borlaug, Barry A , Nelson, Micheal D

Mayo Clinic

Circulation | April 12, 2021 | Volume: 143 | Issue: 15 | Pages: 1499-1501

10.1161/circulationaha.120.053026 | PMID 33844580 Get It

Venetoclax with azacitidine or decitabine in blast‐phase myeloproliferative neoplasm: A multicenter series of 32 consecutive cases
Gangat, Naseema , Guglielmelli, Paola , Begna, Kebede H. , Patnaik, Mrinal M. , Litzow, Mark R. , Al‐Kali, Aref , Foran, James M. , Palmer, Jeanne , Elliott, Michelle A. , Hanson, Curtis A. , Pardanani, Animesh , Mannelli, Francesco , Tefferi, Ayalew , Begna, Kebede , Patnaik, Mrinal , Litzow, Mark R. , Palmer, Jeanne M., Elliott, Michelle , Pardanani, Animesh , Mannelli, Francesco , Vannucchi, Alessandro M , Tefferi, Ayalew , Guglielmelli, Paola , Szuber, Natasha , Alkhateeb, Hassan B. , Vannucchi, Alessandro M.

Mayo Clinic

American Journal of Hematology | April 12, 2021 | Volume: 96 | Issue: 7 | Pages: 781-789

10.1002/ajh.26186 | PMID 33844862 Get It

Abstract Venetoclax (Ven) combined with a hypomethylating agent (HMA) has now emerged as an effective treatment regimen for acute myeloid leukemia, in both de novo and relapsed/refractory setting. The current multicenter study retrospectively examined Ven + HMA treatment outcome among 32 patients (median age 69 years; 59% males) with blast‐phase myeloproliferative neoplasm (MPN‐BP). Pre‐leukemic phenotype included essential thrombocythemia (ET)/post‐ET myelofibrosis (34%), polycythemia vera (PV)/post‐PV myelofibrosis (38%) and primary myelofibrosis (28%). Twenty‐nine study patients were fully annotated cytogenetically and molecularly (NGS): 69% harbored complex karyotype and/or mutations, including TP53 (41%), IDH1/2 (21%), ASXL1 (21%), N/KRAS (14%), SRSF2 (10%), EZH2 (10%) and U2AF1 (7%). All patients received Ven combined with either azacitidine ( n = 12) or decitabine ( n = 20); either up front ( n = 23) or after failing another induction therapy ( n = 9). Complete remission with (CR) or without (CRi) count recovery was achieved in 14 (44%) patients and was more likely to occur in the absence of pre‐leukemic PV/post‐PV myelofibrosis phenotype ( p < .01), complex karyotype ( p < .01) or K/NRAS ( p = .03) mutations; seven of eight patients (88%) without vs four of 21 (19%) with complex karyotype or K/NRAS mutation achieved CR/CRi ( p < .01); all 11 informative patients with pre‐leukemic PV/post‐PV myelofibrosis phenotype displayed complex karyotype ( p < .01). In contrast, neither TP53 ( p = .45) nor IDH1/2 ( p = .63) mutations affected response. Compared to historical controls treated with HMA alone ( n = 26), the CR/CRi rate (44% vs 4%) and median survival (8 vs 5.5 months) were more favorable with Ven + HMA, but without significant difference in overall survival. Importantly, six patients with CR/CRi subsequently received allogeneic hematopoietic stem cell transplant (AHSCT). Note, Ven + HMA produces robust CR/CRi rates in MPN‐BP, especially in the absence of RAS mutations and complex karyotype, thus enabling AHSCT, in some patients.
Two-Sample Mendelian Randomization Analysis of Associations Between Periodontal Disease and Risk of Cancer
Corlin, Laura , Ruan, Mengyuan , Tsilidis, Konstantinos K. , Bouras, Emmanouil , Yu, Yau‐Hua , Stolzenberg‐Solomon, Rachael Z. , Klein, Alison P. , Risch, Harvey A. , Sakoda, Lori C. , Vodička, Pavel , Rish, Pai K, Beck, James D. , Michaud, Dominique S. , Stolzenberg-Solomon, Rachael , Sakoda, Lori C , Platz, Elizabeth A. , Michaud, Dominique S , Klein, Alison P , Tsilidis, Konstantinos K , Risch, Harvey A , Bouras, Emmanouil , Vodicka, Pavel , Amos, Christopher I.

Mayo Clinic

JNCI Cancer Spectrum | April 12, 2021 | Volume: 5 | Issue: 3 | Pages: No page available

10.1093/jncics/pkab037 | PMID 34222791 Get It

Abstract Background Observational studies indicate that periodontal disease may increase the risk of colorectal, lung, and pancreatic cancers. Using a 2-sample Mendelian randomization (MR) analysis, we assessed whether a genetic predisposition index for periodontal disease was associated with colorectal, lung, or pancreatic cancer risks. Methods Our primary instrument included single nucleotide polymorphisms with strong genome-wide association study evidence for associations with chronic, aggressive, and/or severe periodontal disease (rs729876, rs1537415, rs2738058, rs12461706, rs16870060, rs2521634, rs3826782, and rs7762544). We used summary-level genetic data for colorectal cancer (n = 58 131 cases; Genetics and Epidemiology of Colorectal Cancer Consortium, Colon Cancer Family Registry, and Colorectal Transdisciplinary Study), lung cancer (n = 18 082 cases; International Lung Cancer Consortium), and pancreatic cancer (n = 9254 cases; Pancreatic Cancer Consortia). Four MR approaches were employed for this analysis: random-effects inverse-variance weighted (primary analyses), Mendelian Randomization-Pleiotropy RESidual Sum and Outlier, simple median, and weighted median. We conducted secondary analyses to determine if associations varied by cancer subtype (colorectal cancer location, lung cancer histology), sex (colorectal and pancreatic cancers), or smoking history (lung and pancreatic cancer). All statistical tests were 2-sided. Results The genetic predisposition index for chronic or aggressive periodontitis was statistically significantly associated with a 3% increased risk of colorectal cancer (per unit increase in genetic index of periodontal disease; P = .03), 3% increased risk of colon cancer (P = .02), 4% increased risk of proximal colon cancer (P = .01), and 3% increased risk of colorectal cancer among females (P = .04); however, it was not statistically significantly associated with the risk of lung cancer or pancreatic cancer, overall or within most subgroups. Conclusions Genetic predisposition to periodontitis may be associated with colorectal cancer risk. Further research should determine whether increased periodontitis prevention and increased cancer surveillance of patients with periodontitis is warranted.
Commentary on: Nonsurgical Correction of Secondary Contour Deformities of the Penile Girth
Vyas, Krishna S. , Martinez-Jorge, Jorges

Mayo Clinic

Aesthetic Surgery Journal | April 12, 2021 | Volume: 41 | Issue: 8 | Pages: 950-951

10.1093/asj/sjab182 | PMID 33844011 Get It

Invasive carcinoma versus pseudoinvasion: interobserver variability in the assessment of left-sided colorectal polypectomies
Lee, Michael J. , Portillo, Armando Del , Lee, Hwajeong , Pittman, Meredith E. , Sepulveda, Antonia R. , Lagana, Stephen M. , Lee, Michael , Lee, Hwajeong , Salomao, Marcela A, Kudose, Satoru , Ko, Huaibin M. , Salomao, Marcela

Mayo Clinic

Journal of Clinical Pathology | April 12, 2021 | Volume: 75 | Issue: 9 | Pages: 593-597

10.1136/jclinpath-2021-207406 | PMID 33846218 Get It

Objectives Misplaced epithelium in adenomas can occasionally be difficult to distinguish from invasive adenocarcinoma. We evaluated interobserver variability in the assessment of left-sided colon polypectomies for pseudoinvasion versus invasive adenocarcinoma and further investigated relevant histological findings. Methods 28 consecutive left-sided colon polyps with the keywords “pseudoinvasion”, “epithelial misplacement”, “herniation”, “prolapse” or “invasive adenocarcinoma” were collected from 28 patients and reviewed by eight gastrointestinal pathologists. Participants assessed stromal hemosiderin, lamina propria/eosinophils surrounding glands, desmoplasia, high grade dysplasia/intramucosal adenocarcinoma and margin status and rendered a diagnosis of pseudoinvasion, invasive adenocarcinoma, or both. Results Agreement among pathologists was substantial for desmoplasia (κ=0.70), high grade dysplasia/intramucosal adenocarcinoma (κ=0.66), invasive adenocarcinoma (κ=0.63) and adenocarcinoma at the margin (κ=0.65). There was moderate agreement for hemosiderin in stroma (κ=0.53) and prolapse/pseudoinvasion (κ=0.50). Agreement was low for lamina propria/eosinophils around glands (κ=0.12). For invasive adenocarcinoma, seven or more pathologists agreed in 24 of 28 cases (86%), and there was perfect agreement in 19/28 cases (68%). For pseudoinvasion, seven or more pathologists agreed in 19 of 28 cases (68%), and there was perfect agreement in 16/28 cases (57%). Conclusion Moderate to substantial, though imperfect, agreement was achieved in the distinction of pseudoinvasion from invasive carcinoma.